comparemela.com

Latest Breaking News On - Sino biopharm - Page 15 : comparemela.com

invoX Pharma to Acquire F-star Therapeutics, Inc a Pioneering Next Generation Bispecific Discovery Platform and Clinical Programs

invoX Pharma (“invoX”), a wholly owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK), focused on research and development (R&D) and business development activities outside of China, and F-star Therapeutics, Inc. (“F-star”) (NASDAQ:FSTX), a clinical-stage biopharmaceutical company .

Week In Review: invoX, A Sino Biopharm Company, To Pay $161 Million To Acquire F-Star

invoX Pharma, a Sino Biopharm subsidiary, will pay $161 million to acquire F-Star, a Cambridge, UK clinical-stage company developing bispecific drugs for immunotherapies.

invoX Pharma to Acquire F-Star Therapeutics (FSTX) for $7 12 Per Share

invoX Pharma to Acquire F-Star Therapeutics (FSTX) for $7 12 Per Share
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Five things for pharma marketers to know: Friday, June 24, 2022

FDA outlines when it will pull a drug’s breakthrough status; Publix won’t offer COVID-19 vaccines to children under 5.

F-star Therapeutics Shares Soar on Buyout Deal

F-star Therapeutics Shares Soar on Buyout Deal
morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.